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Incontinence-associated dermatitis (IAD) 
describes skin damage associated with 
exposure to urine or faeces. It causes patients 
significant discomfort and can be difficult and 
time-consuming to treat (Doughty, 2012). It 
is a significant health challenge and a well-
documented risk factor for pressure ulcer
development (Beeckman et al, 2014). 
The current lack of standard terminology and definitions is 
hampering clinicians as they attempt to deliver evidence-based 
practice. There are a number of definitions used to describe 
IAD, they include: perineal dermatitis, perineal rash, nappy rash/
dermatitis, irritant dermatitis, moisture ulcers and moisture 
lesions. Establishing consistent terminology for IAD is crucial 
in facilitating research and improving education for healthcare 
professionals and standardising care. 
OVERCOMING THE CHALLENGES
IAD presents a significant challenge to HCPs and patients. The 
exact size of the challenge is hard to define. This is due partly to 
inconsistencies in terminology, and difficulties in recognising the 
condition and distinguishing it from Category I/II pressure ulcers 
in diagnosis: all of which have subsequently resulted in less than 
robust data collection. This is compounded by the lack of a nationally 
recognised, validated and accepted method for IAD data collection, 
which adds to the wide variation in prevalence and incidence figures. 
Studies have estimated prevalence of IAD at 5.6% to 50% (Bliss 
et al, 2006; Peterson et al, 2006; Junkin & Selekof, 2007; Gray 
et al, 2012; Campbell et al, 2014) while incidence is 3.4% to 25% 
(Bliss et al, 2007; Long et al, 2014; Borchert et al, 2010).
Patients with IAD may experience discomfort, pain, burning, 
itching and tingling in affected areas, even when the dermis 
is intact. In addition, patients may feel loss of independence, 
disruption to activities and/or sleep and reduced quality of life that 
becomes worse as the frequency and quantity of soiling increases. 
They may also feel/believe they are a burden on family and friends. 
Cost concerns and constraints
What is the cost of treating IAD?
Accurate costs related to IAD are difficult to present, as there 
are little data that distinguishes these from pressure ulcer costs. 
However, Bale et al (2004) published economic considerations in 
terms of nursing time and consumables in relation to managing 
and treating IAD. Following the introduction of structured 
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skin care regimens in two nursing homes, the presence of IAD and 
Category I pressure damage after three months was reduced, with a 
reduction in time taken to deliver skin care, saving just over 34 minutes 
of staff time per patient per day. 
The average saving per day per patient in staff costs was £8.83  
(US $13.75) for qualified staff and £3.43 (US $5.33) for unqualified 
staff (based on 2004 costs). Guest et al (2011) evaluated the 
economics of four different skin care regimens in over 900 nursing 
home residents, it showed no significant difference in IAD rates 
between the four regimens, however the total cost (including product, 
labour and other supplies) per incontinence episode was significantly 
lower when a barrier film was used.
What is the impact on outcomes and human cost of not managing and 
treating IAD effectively? 
The impact of suffering with IAD on an individual can be undignified 
and painful. A number of patients who suffer from IAD tend to be 
vulnerable and reliant on others to help manage their continence 
issues. Unfortunately there is limited empirical evidence to support 
this. It can only be assumed from anecdotal evidence and working 
within clinical practice that the trauma experienced by individuals has 
a negative impact on their life. This is usually demonstrated by the 
pain and discomfort they express when they undergo treatment.
What are the other associated costs — psychosocial, wider healthcare 
organisation costs?
Clinicians are aware that IAD causes pain and discomfort to patients; 
a stance supported by research from Fader et al (2008). This 
highlights that both urinary and faecal incontinence have a profound 
and devastating effect on a person’s social, physical and financial and 
psychological wellbeing. Yet patients still experience pain, discomfort 
and effects on their dignity because of the poor management of IAD. 
Dorman et al (2004) reported that faecal incontinence in hospital 
patients is often overlooked with management of the problem being 
given low priority. At a time when the health service needs to be aware 
of expenditure, it is difficult to assess the expense of barrier products 
and continence aids. 
Within the NHS, cost of products is often calculated by reviewing 
price per unit and amount of products purchased. However, these 
costs can be unreliable due to insufficient monitoring of incidence and 
prevalence of IAD making it difficult to understand fully the financial 
costs associated with this issue. Regular audit of practice, appropriate 
use of products and their effectiveness would allow for estimates of the 
true cost of managing IAD and the impact on the NHS.
Authors: Ousey K, O’Connor L. Full author details are on page 6 
In the World Health Organization (WHO) International 
Classification of Diseases, which has been in use since 1994, 
there is no coding for IAD, although there is a code  
for nappy dermatitis.
Box 1. ClassificationIntroduction
wDIAGNOSIS
What is the cost of treating IAD? 
IAD and pressure ulcers have a number of common risk factors; 
both are likely to occur in patients with underlying poor health and 
restricted mobility (Langemo et al, 2011; Demarre et al, 2014). 
However, there are distinct differences, see Table 1 and Box 3.
IAD has different aetiologies from pressure ulcers but the two can 
co-exist. IAD is ‘top down’ injury where damage is initiated on 
the surface of the skin; conversely pressure ulcers develop when 
damage is initiated by changes in the soft tissue below and within 
the skin and it is, therefore, coined a ‘bottom up’ injury (Figure 1).
It is important that clinicians are aware of and recognise the 
differences that exist between IAD and pressure ulcers (Table 1).
Grading of IAD
In 2011, Bianchi and Johnstone found that there was no 
consistency in the language used to describe the degree of 
IAD. To minimise inconsistency in accurately grading the 
degree of skin damage and to aid development of management 
strategies, the National Association of Tissue Viability Nurses 
Scotland (NATVNS) established an excoriation grading tool. It 
comprises clinical images, grades the level of excoriation and 
offers management solutions. It aims to encourage a consistent 
approach to IAD care (Bianchi, 2012) (Table 2). 
ASSESSMENT TOOLS
What is available currently?
1. IAD Assessment Intervention Tool (IADIT) (Junkin, 2014)
2. Incontinence-associated dermatitis and its severity (IADS) 
(Borchert et al, 2010)
3. Skin Assessment Tool (Beeckman et al, 2011; Kennedy & 
Lutz, 1996) 
4. IAD Severity Classification Tool (currently being validated) 
(Beeckman et al, 2015)
5. Perineal Assessment Tool (Nix, 2002)
6. Perirectal Skin Assessment Tool (Brown 1993, Brown & Sears, 
1993).
Are there any other assessment tools available?
The All Wales Tissue Viability Nurse Forum and All Wales 
Continence Forum recommends using the All Wales Continence 
Bundle (acute settings)(2013) and the All Wales Bladder and Bowel 
Pathway (community)  (Welsh Assembly Government, 2006). It 
suggests the initial patient assessment should include a complete 
clinical history, physical examination including visual examination 
of perineal areas to exclude other pathologies (such as allergies or 
atrophic vaginitis), an assessment of mobility, dexterity and cognitive 
function, urinalysis, a frequency volume chart and a bowel diary, a 
post-void residual urine test and a review of the patient’s medication 
(The All Wales Tissue Viability Nurse Forum and All Wales 
Continence Forum, 2014). 
It is essential that clinicians assess accurately the cause of skin 
damage allowing for correct diagnosis of IAD or pressure ulcers.
All patients with urinary and/or faecal incontinence should be 
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n	 Blanchable erythema
n	 Glistening appearance of the skin due to serous exudate
n	 Partial thickness skin loss (denudation, erosion, abrasion or 
superficial ulceration of the injured skin)
n	 Vesicles (bullae) containing clear exudate
Box 2. Clinical characteristics of IAD
Figure 1. Possible mechanisms of action in IAD and pressure ulcer development (Wounds International, 2016)
Type of continence 
1. Faecal incontinence (diarrhoea/formed stool) 
2. Double incontinence (faecal and urinary) 
3. Urinary incontinence
What to look out for
n	 Frequent episodes of incontinence (especially faecal)
n	 Use of occlusive containment products
n	 Poor skin condition
n	 Compromised mobility
n	 Diminished cognitive awareness
n	 Poor personal hygiene
n	 Pain
n	 Pyrexia
n	 Medication (antibiotics, immunosuppressants)
n	 Poor nutrition 
n	 Critical illness
Box 3. Risk factors for IAD 
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assessed regularly to check, monitor and document signs of IAD. 
Clinicians should check for signs at least once daily, increasing 
the number of checks based on the number of episodes of 
incontinence. During checks special attention should be given to 
skin folds or areas where soilage or moisture may be trapped (Box 
4, page 4). Regular assessment results in timely and appropriate 
skin cleansing and protection, which can prevent and heal IAD.
3 4
Table 1. Differentiation between IAD and a pressure ulcer [adapted from Back et al, 2011 and Beeckman et al, 2011; published by 
Wounds International 2015]
Parameter IAD Pressure ulcer
History Urinary and/or faecal incontinence Exposure to pressure/shear
Symptoms Pain, burning, itching, tingling Pain
Location Affects perineum, perigenital area; buttocks; gluteal 
fold; medial and posterior aspects of upper thighs; 
lower back; may extend over bony prominence
Usually over bony prominence or associated with 
location of a medical device
Shape/edges Affected area is diffuse with poorly-defined edges/ 
may be blotchy
Distinct edges or margins
Presentation/depth Intact skin with erythema 
(blanchable/non-blanchable), 
with/without superficial/ 
partial-thickness skin loss
1. Presentation varies from  
intact skin with  
non-blanchable erythema  
to full-thickness skin loss
2. Base of wound may  
contain non-viable tissue
Other Secondary superficial skin infection (e.g. candidiasis) 
may be present
Secondary soft tissue infection may be present
TREATMENT
Ultimately the goal of a clinician treating a patient with IAD is to 
manage incontinence (Cooper 2011). However, while progress 
towards this goal is being achieved it is crucial to follow a 
structured cleansing and protection routine.
Managing incontinence 
To assist clinicians in managing incontinence the cause needs 
Table 2. IAD Severity Categorisation Tool
Clinical presentation Severity of IAD Signs**
No redness and skin intact (at risk) Skins is normal as compared to rest of body (no signs of IAD)
Category 1 – Red* but skin intact (mild) Erythema +/- oedema
Category 2 – Red* with skin breakdown 
(moderate—severe)
As above for Category 1
+/- vesicles/bullae/skin erosion
+/- denudation of skin
+/- skin infection
*Or paler, darker, purple, dark red or yellow in patients with darker skin tones 
** If the patient is not incontinent, the condition is not IAD
©NPUAP ©NPUAP
©NPUAP
 Table 3. Characteristics of the main types of skin protectant ingredients (taken from Wounds International Best Practice Principles: 
Incontinence-associated dermatitis — moving prevention forward, 2015)
Principal skin 
protectant ingredient
Description Notes
Petrolatum 
(petroleum jelly)
n	 Derived from petroleum 
processing
n	 Common base for 
ointments
n	 Forms an occlusive layer, increasing skin hydration
n	 May affect fluid uptake of absorbent incontinence products
n	 Transparent when applied thinly
Zinc oxide n	 White powder mixed 
with a carrier to form an 
opaque cream, ointment 
or paste
n	 Can be difficult and uncomfortable to remove (e.g. thick, viscous pastes)
n	 Opaque, needs to be removed for skin inspection 
Dimethicone n	 Silicone-based; also 
known as siloxane
n	 Non-occlusive, does not affect absorbency of incontinence products when  
used sparingly
n	 Opaque or becomes transparent after application
n	 Available products include Remedy Moisturising Barrier Cream
Acrylate terpolymer n	 Polymer forms a 
transparent film on  
the skin
n	 Does not require removal
n	 Transparent, allows skin inspection
n	 Available products include Sureprep Barrier Film
Cyanoacrylate skin 
bonding polymer
n	 Monomer liquid 
chemically bonds to 
stratum corneum, forming 
in situ polymer film
n	 Does not require removal
n	 Transparent, allows skin inspection
n	 Available products include Marathon
madeeasyIAD
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to be identified and a plan of care implemented. The European 
Association of Urology (EAU) Working Panel on Urinary 
Incontinence (UI) (2016) agrees that a clear patient history 
should be taken when assessing a patient with incontinence. 
This assessment should include details of type, timing and 
severity of UI, which will allow for the clinician to categorise into 
stress urinary incontinence, urgency urinary incontinence or 
mixed urinary incontinence. For the older person the EAU advises 
that physiological changes with ageing lead to UI becoming more 
common and co-existent with comorbid conditions, reduced 
mobility and impaired cognition
For reversible causes Gray (2014) suggests non-invasive 
interventions including toileting techniques or nutritional and 
fluid management with Palese & Carniel (2011) recommending 
incontinence management products that can manage fluids. 
Morris (2011) identifies invasive interventions including 
indwelling catheters, faecal management systems and faecal 
pouches (Gray, 2014). A structured skin care protocol should be 
implemented for every patient.
A structured skin care regimen
Skin cleansing
As part of the prevention and management of IAD it is important 
that skin cleansing takes place. Cleansing of the skin should occur 
following every episode of incontinence to ensure that the natural 
function of the skin is maintained. This is supported by a Wounds 
UK 2012 Best Practice Statement which states that when the skin is 
exposed to urine and faeces the pH around the perinatal changes, 
increasing lipase and protease activity, causing an increase in skin 
permeability and reducing the skin’s natural barrier function. 
The use of soaps to cleanse the skin should be avoided as these 
can dehydrate the skin and cause irritation (Bale et al, 2004). 
The use of cleansing/moisturising products is preferable. The 
products can be foam cleansers, wipes or emollients that will 
cleanse the skin and moisturise at the same time thus reducing 
skin irritation and dehydration. Manufacturers’ instructions 
should be followed at all times when using products to ensure 
effective use.
1. Areas of skin that may be affected include:
n	 Perinium
n	 Perigenital areas
n	 Buttocks
n	 Gluteal fold
n	 Thighs
n	 Lower back
n	 Lower abdomen and skin folds (groin, under large 
abdominal pannus etc…)
2. These areas should be checked for:
n	 Maceration
n	 Erythema
n	 Presence of lesions (vesicles, papules, pustules etc…)
n	 Erosion or denudation
n	 Signs of fungal or bacterial skin infection 
Box 4. Skin assessment for incontinence patient at risk 
of IAD (adapted from Wounds International, 2015)
w
w
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Following cleansing of the skin to avoid further irritation and skin 
damage, it is advisable to pat the skin dry rather than rub the 
skin, which can cause breakdown, pain and discomfort.
Skin protection
The principle of applying skin barrier products is to avoid tissue 
breakdown. There are a number of products on the market that can 
be used. These help to maintain the natural barrier function of the 
skin and should be applied according to manufacturers’ instructions. 
Products are available in creams and wipes, spray and foam 
films. Cream products tend to need to be applied after every 
episode of incontinence; other preparations can provide up to 
72 hours protection. Creams should be applied thinly to ensure 
they are absorbed into the skin, providing effective protection and 
preventing continence aids, such as pads, from clogging. 
A new class of robust film formers that are solvent free, and bond 
directly to skin, is also available, these are cyanoacrylates, and are 
differentiated from more common acrylate films. 
When considering an appropriate barrier product, clinicians need to 
be aware of functions of the product. Products tend to form either 
protective or moisturising barriers: protective barriers with silicone 
polymers contain dimethicone, which creates a dry water-repellent 
barrier, protecting against excess moisture; moisture barrier 
products lock in moisture to hydrate and protect the skin (All Wales 
Tissue Viability Forum and All Wales Continence Forum, 2014).
Remedy™ is a silicone blend barrier cream made by Medline — it 
is a barrier film that moisturises the skin, allows it to breathe and 
provides skin protection (Collier & Simon, 2016; Young et al, 2014).
Marathon‰ is a cyanoacrylate-based liquid skin protectant that 
sets up a robust barrier on skin in small, focused areas of high-risk 
skin (Singer et al, 2015; Woo, 2014).
MOVING FORWARD
Reducing knowledge gaps
There has been a range of campaigns to raise awareness of 
pressure ulcer prevention over the past decade, including 
Stop the Pressure Day, React to Red, Your Turn, zero pressure 
campaigns and the introduction of a range of care bundles, 
including SSKIN. These have resulted in a heightened awareness 
and understanding of prevention, management and treatment 
of pressure damage that has successfully reduced incidence. 
There now needs to be similar campaigns to raise awareness and 
understanding of IAD in healthcare with updates for pressure 
ulcer prevention including IAD. 
Product selection remains a challenge for clinicians when preventing 
and managing IAD due to a lack of knowledge and clinical evidence 
(Beeckman et al, 2015). 
Production of standard statements to promote best practice 
and agreed terminology for skin damage caused by excessive 
Figure 2. Treatment pathway algorithm
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moisture would also allow for practice to be measured and 
improved against national guidance.  
There is a need for standardisation of terminology, diagnosis and 
care — how could this be achieved and what improvement would it 
bring to patients, clinicians and payers?
Beeckman et al (2015) highlighted the importance of agreeing and 
recognising consistent terminology for IAD, arguing that the World 
Health Organization’s International Classification of diseases 
does not contain separate coding for IAD. Currently only diaper 
dermatitis is recognised. 
Beeckham et al (2014) suggest that IAD should be clearly 
differentiated, defined and included in the International 
Classification of Diseases, which would facilitate research 
and improve education of healthcare providers. Consistent 
terminology relating to pressure ulcers has allowed organisations 
to benchmark internally, locally and nationally.  
It is essential that healthcare organisations work together to 
provide clear assessment, treatment and evaluation strategies to 
recognise and manage IAD. This will allow for continuity of care by 
healthcare providers, and education for clinicians and patients. 
It also is to be noted that there is a great deal of co-relation between 
the incidences of IAD and pressure ulceration. In particular, skin care 
regimens that are known to reduce pressure ulceration, are likely to 
have done so, at least in part, by the control of IAD.  
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